Use of Single Point Mutations in Domain I of β2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies1

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Immunology

• Publication date

  2002-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.169.12.7097PMID 12471146
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of ‘antiphospholipid’ antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding β2‐glycoprotein I and prothrombin

  2001cited by this paper
• Heterogeneous Recognition of beta 2-glycoprotein I by Antibodies from Antiphospholipid Syndrome Patients

  2000cited by this paper
• 2-glycoprotein Ianti-2-glycoprotein I Interaction

  2000cited by this paper
• Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources.

  2000cited by this paper
• Testing for and Clinical Significance of Anticardiolipin Antibodies

  1999cited by this paper
• Crystal structure of human β2‐glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome

  1999cited by this paper
• Adhesion mechanism of human β2‐glycoprotein I to phospholipids based on its crystal structure

  1999cited by this paper
• Rarity of autoantibodies to a major autoantigen, thyroid peroxidase, that interact with denatured antigen or with epitopes outside the immunodominant region

  1999cited by this paper
• Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53

  1999cited by this paper
• Target Recognition of β2-Glycoprotein I (β2GPI)-Dependent Anticardiolipin Antibodies: Evidence for Involvement of the Fourth Domain of β2GPI in Antibody Binding

  1998cited by this paper
• Heterogeneity and Immunochemical Properties of Anti-β2-glycoprotein I Autoantibodies

  1998cited by this paper
• All-atom empirical potential for molecular modeling and dynamics studies of proteins.

  1998cited by this paper
• Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects.

  1998cited by this paper
• Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding.

  1998cited by this paper
• 抗β2糖蛋白質I(β2GPI)自己抗体はβ2GPIの第一ドメイン上のエピトープを認識する

  1998cited by this paper
• A chemically defined, toleragen-based approach for targeting anti-β2-glycoprotein I antibodies

  1998cited by this paper
• Detection of anti-recombinant ββ2-glycoprotein 1 and anti-recombinant ββ2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus

  1998cited by this paper
• Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI

  1998cited by this paper
• Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system.

  1996cited by this paper
• Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity.

  1996cited by this paper
• Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding.

  1996cited by this paper
• Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome.

  1995cited by this paper
• beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome.

  1994cited by this paper
• Comparative protein modelling by satisfaction of spatial restraints.

  1993cited by this paper
• A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with Infection

  1992cited by this paper
• Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I.

  1991cited by this paper
• Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons

  1991cited by this paper
• The chemistry and mechanism of antibody binding to protein antigens.

  1988cited by this paper

• Obstetric antiphospholipid syndrome: Advances in pathogenesis.

  2026cites this paper
• The J-shape of β2GPI reveals a cryptic discontinuous epitope across domains I and II

  2025influential citation
• Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis

  2025cites this paper
• Diagnosis of Antiphospholipid Syndrome by Chemiluminescent or Enzyme-Linked Immunosorbent Assay – A Comparison Study and Comprehensive Literature Review

  2025cites this paper
• Protection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation.

  2025cites this paper
• Domain and Residue Mapping of Autoantibodies to β2GPI Reveals Differences Among Antiphospholipid Syndrome Phenotypes.

  2025cites this paper
• TO SHOw how we have been ENgaged in the APS FiELD (What we learned on APS collaborating with Professor Yehuda Shoenfeld).

  2024cites this paper
• Understanding the structure of β2-glycoprotein I: new insights and future paths for antiphospholipid syndrome

  2024cites this paper
• Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

  2023influential citation
• 16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends

  2023cites this paper
• Protection of β2GPI Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation

  2023cites this paper
• Evolution of Antiphospholipid Syndrome

  2023cites this paper
• PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome

  2022cites this paper
• Epitope of antiphospholipid antibodies retrieved from peptide microarray based on R39‐R43 of β2‐glycoprotein I

  2022cites this paper
• Physical properties as antigenic determinant: the example of antiphospholipid antibodies

  2021influential citation
• Cardiolipin interacts with beta‐2‐glycoprotein I and forms an open conformation–Mechanisms analyzed using hydrogen/deuterium exchange

  2021cites this paper
• Molecular Mechanisms of “Antiphospholipid Antibodies” and Their Paradoxical Role in the Pathogenesis of “Seronegative APS”

  2020cites this paper
• Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis

  2020cites this paper
• The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS

  2020cites this paper
• Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study

  2020cites this paper
• Diagnostic biologique du syndrome des antiphospholipides

  2020cites this paper
• The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome

  2020cites this paper
• Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome.

  2019cites this paper
• Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter multiplatform study

  2019cites this paper
• Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome.

  2019cites this paper
• Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation

  2019cites this paper
• Renal involvement in antiphospholipid syndrome

  2018cites this paper
• Antiphospholipid syndrome: An update on risk factors for pregnancy outcome.

  2018cites this paper
• Lysine residues control the conformational dynamics of beta 2-glycoprotein I.

  2018cites this paper
• Update on Antiphospholipid Syndrome: Ten Topics in 2017

  2018cites this paper
• Oxidative post-translational modification of βeta 2-glycoprotein I in the pathophysiology of the anti-phospholipid syndrome.

  2018cites this paper
• Chapter 2 Natural Proteins Involved in Antiphospholipid Syndrome

  2018cites this paper
• PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome

  2018cites this paper
• The clinical value of assays detecting antibodies against domain I of β2-glycoprotein I in the antiphospholipid syndrome.

  2018cites this paper
• Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances

  2017cites this paper
• Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests

  2017cites this paper
• The Clinical Relevance of Noncriteria Antiphospholipid Antibodies

  2017cites this paper
• Antiphospholipid Syndrome

  2017cites this paper
• Patient-derived anti-β2GP1 antibodies recognize a peptide motif pattern and not a specific sequence of residues

  2017cites this paper
• Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.

  2017cites this paper
• Porteurs asymptomatiques d'un profil d'anticorps anti-phospholipides à haut risque

  2017cites this paper
• Natural Proteins Involved in Antiphospholipid Syndrome

  2017cites this paper
• Antiphospholipid syndrome and kidney disease.

  2017cites this paper
• Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis

  2017cites this paper
• Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome

  2017cites this paper
• The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome

  2017cites this paper
• The Fifth Domain of Beta 2 Glycoprotein I Protects from Natural IgM Mediated Cardiac Ischaemia Reperfusion Injury

  2016cites this paper
• Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome

  2016cites this paper
• Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome

  2016cites this paper
• Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome

  2016cites this paper
• Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools

  2016cites this paper
• Role of anti‐domain 1‐β2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome

  2016cites this paper
• Non-classification Criteria

  2015cites this paper
• Laboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome

  2015cites this paper
• Antiphospholipid Antibody Mechanisms of Thrombosis

  2015cites this paper
• Antibodies to Domain 1 ( Dm 1 ) of β 2-Glycoprotein 1 ( β 2 GP 1 ) correctly classify patients at risk in Antiphospholipid Syndrome ( APS )

  2015cites this paper
• Antiphospholipid syndrome: antibodies to Domain 1 of β2‐glycoprotein 1 correctly classify patients at risk

  2015cites this paper
• β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome.

  2015cites this paper
• Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome.

  2015cites this paper
• Beta-2 glycoprotein1: function in health and disease

  2014cites this paper
• Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis

  2014cites this paper
• Domain I: the hidden face of antiphospholipid syndrome

  2014cites this paper
• Thrombin generation: innovations and clinical applications

  2014cites this paper
• 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.

  2014cites this paper
• Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome.

  2014cites this paper
• 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

  2014cites this paper
• Reactivity against the Five Domains of β 2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

  2014cites this paper
• New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I Beta-2-Glycoprotein-I Antibodies

  2014cites this paper
• The future of treatment for antiphospholipid syndrome

  2014cites this paper
• The pathogenesis of the antiphospholipid syndrome.

  2013cites this paper
• Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAs

  2013influential citation
• Anti‐β2‐glycoprotein I antibodies

  2013cites this paper
• The Pathogenesis of the Anti phos pho lip id Syndrome

  2013cites this paper
• Seronegative antiphospholipid syndrome.

  2013cites this paper
• thrombosis 2-glycoprotein I cause LAC and their presence correlates strongly with β IgG antibodies that recognize epitope Gly40-Arg43 in domain I of

  2013cites this paper
• What are the Potential Future Treatments in Antiphospholipid Syndrome

  2012cites this paper
• Task Force Report on “Non-criteria” Antiphospholipid Antibody Tests

  2012cites this paper
• Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome.

  2012cites this paper
• Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

  2012cites this paper
• thrombotic disorders Antigen and substrate withdrawal in the management of autoimmune

  2012cites this paper
• Conformation of beta2glycoprotein I and its effect on coagulation.

  2012cites this paper
• Antibodies against domain I of β2-glycoprotein I: the one and only?

  2012cites this paper
• Post-translational oxidative modification of β2-glycoprotein I and its role in the pathophysiology of the antiphospholipid syndrome.

  2012cites this paper
• The significance of autoantibodies against β2-glycoprotein I.

  2012cites this paper
• Therapeutic Potential of Toleragens in the Management of Antiphospholipid Syndrome

  2012cites this paper
• Current International Initiatives in Antiphospholipid Antibody Testing

  2012cites this paper
• Lupus Anticoagulants, Antiphospholipid Antibodies, and Antiphospholipid Syndrome

  2012cites this paper
• SPECIAL ARTICLE Antibodies against domain I of b2-glycoprotein I: the one and only?

  2012cites this paper
• Comparison the Anti-β2GP1 Autoantibody Level in Serum of Pregnant Women with History of Recurrent Miscarriage and Healthy Women in Gorgan

  2012cites this paper
• β₂-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator.

  2011cites this paper
• Evaluating the conformation of recombinant domain I of β2-glycoprotein I and its interaction with human monoclonal antibodies

  2011cites this paper
• Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.

  2011cites this paper
• Antiphospholipid Syndrome during pregnancy: the state of the art.

  2011cites this paper
• ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010

  2011cites this paper
• Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post‐translational modification of beta 2 glycoprotein I

  2011cites this paper
• Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS).

  2011cites this paper
• Antiphospholipid Syndrome: Pathogenesis

  2011cites this paper
• Patient‐derived monoclonal antibodies directed towards beta2 glycoprotein‐1 display lupus anticoagulant activity

  2011cites this paper
• ‘Criteria’ aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010

  2011cites this paper
• β2‐Glycoprotein I: evolution, structure and function

  2011cites this paper